HN Summary

• SHN is leading a global clinical trial testing tebapivat, an investigational oral therapy for sickle cell disease, with Dr. Kevin Kuo serving as lead investigator and SHN named the first site in Ontario to offer the study.

• The trial aims to improve anemia, fatigue, and quality of life for people living with sickle cell disease, assessing both clinical outcomes and patient-reported experiences.

• This research reinforces SHN’s role as a national leader in equitable, community-relevant innovation, expanding access to cutting-edge treatments for a disease that disproportionately affects Scarborough’s diverse population.

Scarborough Health Network (SHN) continues to strengthen its leadership in ground-breaking clinical research, with Dr. Kevin Kuo, Vice President of Research and Innovation and physician lead of the Adult Sickle Cell Disease Clinic, now serving as a lead inavestigator in a new international clinical trial focused on improving outcomes for people living with sickle cell disease (SCD).

The study is recruiting participants from around the world to assess the safety of tebapivat, an investigational oral medication that may help address anemia and fatigue associated with SCD. SHN is one of three hospital sites in Canada to offer this trial, and the first in Ontario, further positioning our organization as a national leader in advancing treatment options for people living with SCD.

“This study represents an important opportunity to expand treatment possibilities for people living with inherited blood disorders like sickle cell,” shared Dr. Kuo. “By leading this trial, SHN is contributing to an international effort that could meaningfully improve the lives of patients who have long faced limited options.”

A new step forward in sickle cell research

SCD is an inherited blood disorder that affects hemoglobin, the molecule responsible for carrying oxygen in the blood. This causes red blood cells to become misshapen and rigid, leading to chronic anemia, pain crises, fatigue, and other complications that can significantly impact quality of life. While current treatments can help manage symptoms, like through the services offered at SHN’s Kids Care and Adult SCD Clinics, there remains an urgent need for new therapies that target the disease more directly.

This trial is exploring whether tebapivat can improve hemoglobin levels and reduce symptoms for patients with SCD who are not receiving regular blood transfusions. The first 12 weeks of the study will compare different doses of tebapivat to a placebo (a look-alike pill with no active medication). After this phase, eligible participants will have the option to continue taking tebapivat in an open-label extension, where everyone knows they are receiving the active treatment.

Key measures will include changes in hemoglobin concentration, markers of red blood cell health, and patient-reported outcomes such as fatigue and pain—helping Dr. Kuo and other researchers involved assess both the clinical and day-to-day impact of the therapy.

Dr. Kuo’s leadership in this trial builds on his extensive experience in rare and complex hematologic diseases. His prior research, including a global study on thalassemia recognized by The Lancet, has positioned him as a leading voice in the field and underscores SHN’s growing influence and leadership, both in academic medicine and SCD care.

Strengthening SHN’s research mission

The tebapivat clinical trial exemplifies SHN’s commitment to advancing equitable, community-relevant research that addresses the health needs of diverse populations. SCD disproportionately affects people of African, Caribbean, Middle Eastern, and South Asian descent: groups that make up a significant portion of Scarborough’s community.

“Dr. Kuo’s work in this clinical trial aligns perfectly with SHN’s mission,” shared Dr. Samir Grover, Executive Vice President of Academics at SHN. “It reflects the excellence and ambition driving our research program. We’re proud to see our clinicians leading new studies that not only advance medical science, but also deliver tangible benefits to the communities we care for.”

With continued investment in research infrastructure and an expanding network of clinician-investigators, SHN is rapidly emerging as a hub for discovery and innovation. Participation in studies like this one ensures that local patients have access to cutting-edge treatments while contributing to the advancement of global medicine.

Through the leadership of physicians like Dr. Kuo, SHN continues to demonstrate what it means to transform care through research, creating new pathways to better health in Scarborough and beyond.